Results 221 to 230 of about 167,455 (238)
Some of the next articles are maybe not open access.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010
Stroke is the third most common cause of death in the United States and is the number one cause of long‐term disability. Legislative mandates, largely the result of the American Heart Association, American Stroke Association, and Brain Attack Coalition working cooperatively, have resulted in nationwide standardization of care for patients who ...
Carolyn Piazza +5 more
openaire +2 more sources
Stroke is the third most common cause of death in the United States and is the number one cause of long‐term disability. Legislative mandates, largely the result of the American Heart Association, American Stroke Association, and Brain Attack Coalition working cooperatively, have resulted in nationwide standardization of care for patients who ...
Carolyn Piazza +5 more
openaire +2 more sources
Acute Ischemic Stroke Management
Thrombosis Research, 2000The use of thrombolytic therapy represents one of many recent developments in the management of acute ischemic stroke. The development of stroke teams and protocols has been driven by these new demands for an urgent response to ischemic stroke. The short time window of 3 hours for therapy with intravenous recombinant tissue plasminogen activator ...
Richard P. Atkinson +1 more
openaire +3 more sources
Thrombolysis for Acute Ischemic Stroke
Neurosurgery Clinics of North America, 1997The use of thrombolytic agents to restore cerebral blood flow is one of the most notable advances in the treatment of ischemic stroke. This article reviews thrombolytic therapy, its limitations, and the techniques by which thrombolytic agents can be delivered.
Dennis M.D. Landis +3 more
openaire +2 more sources
2017
The primary focus for the initial treatment of acute ischemic stroke is determining whether a patient who presents with acute neurological deficits is a candidate for intravenous (IV) thrombolytic therapy. Within the last two decades, the use of IV alteplase (tPA) for acute ischemic stroke together with the establishment of stroke systems of care has ...
Karin Nystrom, Joseph Schindler
openaire +2 more sources
The primary focus for the initial treatment of acute ischemic stroke is determining whether a patient who presents with acute neurological deficits is a candidate for intravenous (IV) thrombolytic therapy. Within the last two decades, the use of IV alteplase (tPA) for acute ischemic stroke together with the establishment of stroke systems of care has ...
Karin Nystrom, Joseph Schindler
openaire +2 more sources
Alteplase for acute ischemic stroke
Expert Review of Cardiovascular Therapy, 2006Alteplase, an intravenously administered form of recombinant tissue plasminogen activator (rt-PA), remains the only US FDA-approved thrombolytic treatment for acute ischemic stroke within 3 h of symptom onset. Patients treated with intravenous rt-PA are at least 30% more likely to have minimal or no disability at 3 months compared with placebo. Despite
Nicole R. Gonzales, James C. Grotta
openaire +2 more sources
Management of Acute Ischemic Stroke
Mayo Clinic Proceedings, 2004The treatment of acute ischemic stroke has evolved from observation and the passage of time dictating outcome to an approach that emphasizes time from ictus, rapid response, and a dedicated treatment team. We review the treatment of acute ischemic stroke from the prehospital setting, to the emergency department, to the inpatient hospital setting.
Timothy J. Ingall +5 more
openaire +3 more sources
Treatment of Acute Ischemic Stroke
New England Journal of Medicine, 2000Ischemic stroke exacts a heavy toll in death and disability worldwide. In the United States, where it is the third leading cause of death and the leading cause of serious long-term disability, approximately 750,000 strokes occur annually, with an annual mortality rate exceeding 150,000.1–4 In June 1996, the Food and Drug Administration (FDA) approved ...
Thomas Brott, Julien Bogousslavsky
openaire +3 more sources
Acute Ischemic Stroke and Infections
Journal of Stroke and Cerebrovascular Diseases, 2011We present an overview of multiple infections in relation to acute ischemic stroke and the therapeutic options available. Conditions that are a direct cause of stroke (infectious endocarditis, meningoencephalitides, and human immunodeficiency virus infection), the pathophysiologic mechanism responsible for stroke, and treatment dilemmas are presented ...
Kevin J. Gibbons +11 more
openaire +3 more sources
Treatment of acute ischemic stroke
Journal of Stroke and Cerebrovascular Diseases, 2001Acute ischemic stroke remains difficult to treat despite the advent of new therapies. The only approved medication to reverse its effects is recombinant tissue plasminogen activator administered intravenously within 3 hours of onset of stroke symptoms--an opportunity that does not often present itself. The principal drawback to thrombolytic therapy for
openaire +3 more sources
Thrombolysis for Acute Ischemic Stroke
Physical Medicine and Rehabilitation Clinics of North America, 1999Data generated from randomized controlled trials in the last decade have shown that acute intervention can improve neurologic outcome in patients with ischemic stroke. This article reviews recent studies of systemic and intra-arterial thrombolysis for cerebrovascular disease in detail.
openaire +3 more sources